Recent publicity around the use of new antiobesity medications (AOMs) has focused the attention of patients and healthcare providers on the role of pharmacotherapy in the treatment of obesity. Newer drug treatments have shown greater efficacy and safety compared with older drug treatments, yet access to these drug treatments is limited by providers’ discomfort in prescribing, bias, and stigma around obesity, as well as by the lack of insurance coverage. Now more than ever, healthcare providers must be able to discuss the risks and benefits of the full range of antiobesity medications available to patients, and to incorporate both guideline based advice and emerging real world clinical evidence into daily clinical practice. The tremendous variability in response to antiobesity medications means that clinicians need to use a flexible approach that takes advantage of specific features of the antiobesity medication selected to provide the best option for individual patients. Future resea
Judge tosses legal challenge alleging ballot measure on hotel worker pay is misleading to voters lbpost.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lbpost.com Daily Mail and Mail on Sunday newspapers.
In 2022, some of the top chronic conditions affecting group benefits plans were diabetes, obesity, depression and arthritis. Diabetes was the No. 1 ranked condition for drug claims in 2022, knocking rheumatoid arthritis down to the No. 2 spot, according to Telus Health’s annual drug plan trends report. And the 2023 Benefits Canada Healthcare Survey […]
Council, the people have spoken on this proposed rates rise westernadvocate.com.au - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from westernadvocate.com.au Daily Mail and Mail on Sunday newspapers.